The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effect of the Affordable Medicines Facility—malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data
Abstract
Background Malaria is one of the greatest causes of mortality worldwide. Use of the most effective treatments for malaria remains inadequate for those in need, and there is concern over the emergence of resistance to these treatments. In 2010, the Global Fund launched the Affordable Medicines Facility--malaria (AMFm), a series of national-scale pilot programmes designed to increase the access and use of quality-assured artemisinin based combination therapies (QAACTs) and reduce that of artemisinin monotherapies for treatment of malaria. AMFm involves manufacturer price negotiations, subsidies on the manufacturer price of each treatment purchased, and supporting interventions such as communications campaigns. We present findings on the effect of AMFm on QAACT price, availability, and market share, 6-15 months after the delivery of subsidised ACTs in Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania (including Zanzibar). Methods We did nationally representative baseline and endpoint surveys of public and private sector outlets that stock antimalarial treatments. QAACTs were identified on the basis of the Global Fund's quality assurance policy. Changes in availability, price, and market share were assessed against specified success benchmarks for 1 year of AMFm implementation. Key informant interviews and document reviews recorded contextual factors and the implementation process. Findings In all pilots except Niger and Madagascar, there were large increases in QAACT availability (25·8-51·9 percentage points), and market share (15·9-40·3 percentage points), driven mainly by changes in the private for-profit sector. Large falls in median price for QAACTs per adult equivalent dose were seen in the private for-profit sector in six pilots, ranging from US$1·28 to $4·82. The market share of oral artemisinin monotherapies decreased in Nigeria and Zanzibar, the two pilots where it was more than 5% at baseline. Interpretation Subsidies combined with supporting interventions can be effective in rapidly improving availability, price, and market share of QAACTs, particularly in the private for-profit sector. Decisions about the future of AMFm should also consider the effect on use in vulnerable populations, access to malaria diagnostics, and cost-effectiveness. Funding The Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Bill & Melinda Gates Foundation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two references reported on the Affordable Medicines Facility-malaria (AMFm), which provided subsidies to manufacturers of artemisinin-based combination therapies (ACT) at the global level, and which resulted in price reductions for ACTs to consumers36”
In the citing paper
“and increased availability of ACTs in various countries in Sub-Saharan Africa.36 37”
In the citing paper
“An independent evaluation of the effect of AMFm on quality-assured ACT price, availability, and market share was conducted 6–15 months after the delivery of subsidized ACTs in Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania (including Zanzibar).167”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“In all pilots except Niger and Madagascar, there were large increases in ACT availability (25·8–51·9 percentage points), and market share (15·9–40·3 percentage points), driven mainly by changes in the private for-profit sector.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“Large falls in median price for ACTs per adult equivalent dose were seen in the private for-profit sector in six pilots, ranging from US$1·28 to $4·82.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“The market share of oral artemisinin monotherapies decreased in Nigeria and Zanzibar, the two pilots where it was more than 5% at baseline.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“The evaluators concluded that subsidies combined with supporting interventions could be effective in rapidly improving availability, price, and market share of quality-assured ACTs, particularly in the private for-profit sector.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
Citations
Cites
Developing and evaluating complex interventions: the new Medical Research Council guidance
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., & Petticrew, M. (2008) · BMJ · doi:10.1136/bmj.a1655 · Cited by 10,995
Developing and Evaluating Complex Interventions: New Guidance
Craig, P., Dieppe, P. A., MacIntyre, S., Michie, S., Nazareth, I., & Petticrew, M. P. (2006) · UCL Discovery (University College London) · Cited by 1,878
Demographic and Health Surveys
Larmarange, J., Vallo, R., Yaro, S., Méda, N., Ferry, B., Larmarange, J., & Ird, D. (2008) · Choice Reviews Online · doi:10.5860/choice.45-6819 · Cited by 1,455
Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L. J., Nguon, C., Day, N., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2331 · Cited by 658
Chan, M. (2010) · Cited by 513
Institute of Medicine (2004) · National Academies Press eBooks · doi:10.17226/11017 · Cited by 232
Erratum: Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L. J., Nguon, C., Day, N., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2385 · Cited by 221
O’Connell, K. A., Gatakaa, H., Poyer, S., Njogu, J. N., Evance, I., Munroe, E., Solomon, T., Goodman, C. A., Hanson, K., ZINSOU, C., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-326 · Cited by 163
Self-citationSabot, O. J., Mwita, A., Cohen, J. M., Ipuge, Y., Gordon, M., Bishop, D., Odhiambo, M., Ward, L., & Goodman, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006857 · Cited by 105
Self-citationKangwana, B. P., Kedenge, S. V., Noor, A. M., Alegana, V. A., Nyandigisi, A. J., Pandit, J. M., Fegan, G., Todd, J., BROOKER, S. J., Snow, R. W., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000437 · Cited by 82
Self-citationYeung, S., Patouillard, E., Allen, H., & Socheat, D. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-243 · Cited by 75
The ACTwatch project: methods to describe anti-malarial markets in seven countries
Shewchuk, T., O’Connell, K. A., Goodman, C. A., Hanson, K., Chapman, S., & Chavasse, D. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-325 · Cited by 54
Self-citationUniversal access to malaria medicines: innovation in financing and delivery
Adeyi, O., & Atun, R. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61189-0 · Cited by 52
A Global Subsidy: Key To Affordable Drugs For Malaria?
Laxminarayan, R., & Gelband, H. (2009) · Health Affairs · doi:10.1377/hlthaff.28.4.949 · Cited by 47
Hanson, K., Goodman, C. A., Tougher, S., Mann, A. G., Willey, B., Arnold, F., Ye, Y., Ren, R., & Yoder, S. (2012) · Cited by 47
Self-citationYadav, P., Cohen, J. L., Alphs, S., Arkedis, J., Larson, P. S., Massaga, J. J., & Sabot, O. J. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-299 · Cited by 37
Cost is killing patients: subsidising effective antimalarials
Talisuna, A. O., Grewal, P., Rwakimari, J. B., Mpanga-Mukasa, S., Jagoe, G., & Banerji, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61767-0 · Cited by 31
Focusing on Quality Patient Care in the New Global Subsidy for Malaria Medicines
Moon, S., Casas, C. P., Kindermans, J.-M., Smet, M. D., & von Schoen-Angerer, T. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000106 · Cited by 30
Affordable Medicines Facility for malaria
Bate, R., & Hess, K. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70158-6 · Cited by 21
Piloting the Affordable Medicines Facility-malaria: what will success look like?
Yamey, G., Schäferhoff, M., & Montagu, D. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.11.091199 · Cited by 18
Affordable medicines facility for malaria: reasonable or rash?
Kamal-Yanni, M. M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60048-7 · Cited by 12
A path to an optimal future for the Affordable Medicines Facility – malaria
Sabot, O. J., Gordon, M., Moonen, B., Talisuna, A. O., & Amofah, G. K. (2011) · Health Policy and Planning · doi:10.1093/heapol/czr067 · Cited by 11
Cited by
Sorted by citations
Health Care Systems in Low- and Middle-Income Countries
MILLS, A. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1110897 · Cited by 644
Achieving global targets for antimicrobial resistance
Laxminarayan, R., Sridhar, D., Blaser, M. J., Wang, M., & Woolhouse, M. E. J. (2016) · Science · doi:10.1126/science.aaf9286 · Cited by 316
Agyepong, I. A., Sewankambo, N., Binagwaho, A., Coll-Seck, A. M., Corrah, T., Ezeh, A., Fekadu, A., Kilonzo, N., Lamptey, P., Masiye, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31509-x · Cited by 245
Mendelson, M., Røttingen, J., Gopinathan, U., Hamer, D. H., Wertheim, H. F. L., Basnyat, B., Butler, C., Tomson, G. B., & Balasegaram, M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00547-4 · Cited by 205
Montagu, D., & Goodman, C. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30242-2 · Cited by 145
Self-citation
Metadata
- Authors
- Tougher, S., Ye, Y., Amuasi, J. H., Kourgueni, I. A., Thomson, R., Goodman, C., Mann, A. G., Ren, R., Willey, B. A., Adegoke, C. A., Amin, A., Ansong, D., Bruxvoort, K., Diallo, D. A., Diap, G., Festo, C., Johanes, B., Juma, E., Kalolella, A., Malam, O., Mberu, B., Ndiaye, S., Nguah, S. B., Seydou, M., Taylor, M., Rueda, S. T., Wamukoya, M., Arnold, F., & Hanson, K.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- University of Minnesota (US)
- Ifakara Health Institute (TZ)
- ICF International (United States) (US)
- Komfo Anokye Teaching Hospital (GH)
- Drugs for Neglected Diseases Initiative (CH)
- Kenya Medical Research Institute (KE)
- African Population and Health Research Center (KE)
- Institut de Recherche pour le Développement (SN)
- Corresponding author
- Tougher, Sarah
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 380
- Issue
- 9857
- Pages
- 1916-1926
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2122992752
- Cited by
- 173
- References
- 22
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 9 · 2023: 8 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 6 · 2018: 8 · 2017: 26 · 2016: 16 · 2015: 27 · 2014: 23 · 2013: 18 · 2012: 3
- FWCI
- 54.35
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-11-22)
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- Affordable Medicines Facility-malaria, artemisinin-based combination therapy, drug availability, market share, artemisinin monotherapy, drug subsidies, public sector, malaria treatment access, Global Fund, antimalarial drug resistance, Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, Tanzania
- MeSH terms
- Africa, Antimalarials, Humans, Lactones, Malaria, Marketing of Health Services, Pharmacies, Pilot Projects, Drug Costs, Private Sector, Public Sector, Artemisinins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
